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Background:  It is well known that propofol protects myocardium against myocardial ischemia/reperfusion injury in 
the rat heart model.  The aim of this study was to investigate whether propofol provides a protective effect against a 
regional myocardial ischemia/reperfusion injury in an	in vivo rat heart model after 48 h of reperfusion. 
Methods:  Rats were subjected to 25 min of left coronary artery occlusion followed by 48 h of reperfusion.  The 
sham group received profopol without ischemic injury. The control group received normal saline with ischemia/
reperfusion injury.  The propofol group received profopol with ischemia/reperfusion injury.  The intralipid group 
received intralipid with ischemia/reperfusion injury.  A microcatheter was advanced into the left ventricle and the 
hemodynamic function was evaluated.  The infarct size was determined by triphenyltetrazolium staining.  The serum 
level of cardiac troponin-I (cTn-I) was determined by ELISA (enzyme-linked immunosorbent assay). 
Results:  Propofol demonstrated protective effects on hemodynamic function and infarct size reduction.  In the 
propofol group, the +dP/dtmax (P = 0.002) was significantly improved compared to the control group.  The infarct size 
was 49.8% of the area at risk in the control group, and was reduced markedly by administration of propofol to 32.6% 
in the propofol group (P = 0.014).  The ischemia/reperfusion-induced serum level of cTn-I was reduced by propofol 
infusion during the peri-ischemic period (P = 0.0001).
Conclusions:  Propofol, which infused at clinically relevant concentration during the peri-ischemic period, has 
delayed myocardial protective effect after regional myocardial ischemia/reperfusion injury in an in vivo rat heart 
model after 48 h of reperfusion.  (Korean J Anesthesiol 2010; 58: 378-382)
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Introduction
    Propofol has a myocardial protective effect through a range 
of mechanisms, such as oxygen free radical scavenging [1-3], 
blocking of the calcium channel by inhibiting the L-type calcium 
channel [4,5], and inhibiting neutrophil activation [6,7]. The 
myocardial protective effect of propofol has been identified 
by a variety of methods using an ischemia/reperfusion (I/R) 
injury model [1-3,7,8]. However, some technical problems 
make it difficult to perform a long-term follow-up of the my-
ocardial protective effect. Some reports have shown that my-
ocardial infarct size and neutrophil adherence peak at 24 and 
48 h, respectively, after an I/R injury [9,10]. During the late 
reperfusion period, myocardial apoptotic cell death develops 
progressively until 72 h [10]. Therefore, long-term observations 
will be needed to determine whether myocardial protection is a 
temporary or sustained effect [11-13].
    In this study, a regional myocardial I/R injury in an in 
vivo rat heart model was used to determine the effects of a 
clinically relevant propofol concentration during the peri-
ischemic period of anesthesia. After 48 h of reperfusion, the 
hemodynamic function, infarct size, and cardiac troponin-I 
(cTn-I) level were checked to determine whether propofol 
had a delayed myocardial protective effect against a regional 
myocardial I/R injury in an in vivo rat heart model.
Meterials and Methods 
Animal preparation 
    Male Sprague-Dawley rats weighing between 220 and 240 g 
were used. All animals were maintained in accordance with 
the Guidelines for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health in 1996. 
    The animals received general anesthesia with an intramuscular 
injection of 50 mg/kg of ketamine (Ketamine Hcl
Ⓡ, Huons, 
Seoul, South Korea) and 3 mg/kg of zylazine (Rompun
Ⓡ, Bayer, 
Seoul, South Korea). The rats were judged to be awake from 
the anesthesia once their tails moved during the procedure, 
and then 25 mg/kg of ketamine and 1.5 mg/kg of zylazine were 
injected to maintain the level of anesthesia. After anesthesia 
was induced, a heparin-treated 24 G catheter was inserted 
into the femoral vein, and each drug was infused according 
to the protocol. The trachea was intubated, and the rats were 
ventilated mechanically (tidal volume: 8 ml/kg, respiratory rate: 
80 strokes/min) with ambient air using a volume-controlled 
rodent ventilator (Harvard Rodent Ventilator Model 607, 
Harvard, Holliston, MA, USA). The arterial blood pH and gases 
were maintained within normal physiological limits (pH: 7.3-
7.4, PaCO2: 30-40 mmHg, PaO2: 60-100 mmHg).
    A paramedian sternotomy was performed, and the pericardium 
was opened to expose the heart. For the I/R experiments, a 4-0 
black silk, nonabsorbable suture was passed around the left 
coronary artery (LCA) territory to induce regional myocardial 
ischemia. The coronary artery was occluded by pulling a snare 
through a small vinyl chloride tube and clamping it with a 
mosquito hemostat. Reperfusion was achieved by releasing the 
clamp. Myocardial ischemia was confirmed by the appearance 
of regional epicardial cyanosis over the myocardial surface and 
by arrhythmia. After 25 min of ischemia, the myocardium was 
reperfused by loosening the snare, which was maintained for 
48 h of reperfusion. Successful reperfusion was confirmed by 
the disappearance of epicardial cyanosis and the production 
of epicardial hyperemia and arrhythmia after releasing the 
snare. The body temperature was monitored with a rectal 
thermometer and maintained at 36-38
oC using a heating pad. 
Experimental protocols 
    Sixty-four rats were divided randomly into four groups. The 
sham group received a bolus infusion of 2.5 mg/kg of profopol 
(Fresofol
Ⓡ 2%, Fresenius Kabi, Homburg, Germany) followed 
by a continuous propofol infusion at a rate of 200 μg/kg/min, 
which was maintained until 30 min after the sham operation. 
The LCA was not occluded. The control group received 0.3 ml of 
normal saline intravenously followed by a continuous infusion 
of normal saline at a rate of 1.5 ml/h. The propofol group 
received a bolus infusion of 2.5 mg/kg of profopol followed 
by a continuous propofol infusion at a rate of 200 μg/kg/min. 
The intralipid group received a bolus infusion of 0.3 ml of 2% 
intralipid (20% Intralipid
Ⓡ, Fresenius Kabi, Sweden) followed by 
a continuous infusion of 2% intralipid at a rate of 1.5 ml/h. A 25 
min LCA occlusion was produced followed by 48 h of reper    fusion. 
Each drug was administered intravenously 5 min before the 
ischemic insult, and continuous drug infusion was maintained 
until 5 min after reperfusion.
    An additional experiment was performed when a rat died 
during an experiment or during the postexperimental care 
period. An additional experiment was required for five, zero, 
six, and four rats in the control, sham, propofol, and intralipid 
groups, respectively. Two and four rats in the control and 
intralipid groups, respectively, required additional anesthesia. 
The hemodynamic function and infarct weight were checked in 
10 rats of each group. The cardiac troponin-1 (cTn-I) level was 
also checked in six rats from each group. 
Measuring hemodynamic variables and myocardial 
contractility
    After the 48 h reperfusion, the rats were anesthetized with 380 www.ekja.org
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25 mg/kg of ketamine and 1.5 mg/kg of xylazine. The right 
common carotid artery was cannulated with a 2-Fr Millar 
catheter (Model SPR-407, Millar Instruments Inc., Houston, 
TX, USA) and advanced into the left ventricle (LV) to measure 
heart rate (HR), left ventricular systolic pressure (LVSP), left 
ventricular end diastolic pressure (LVEDP), the peak rate of 
intraventricular pressure increase (+dP/dtmax), and the peak 
rate of intraventricular pressure decrease (-dP/dtmax). The 
systolic and diastolic pressures were checked after repositioning 
the catheter to the ascending aorta. 
Determining the areas at risk and infarct size
    After analyzing hemodynamic function, the LCA was occluded 
again, and 1 ml of 2% Evans blue dye was injected into the 
pulmonary artery to determine the areas at risk (AAR). The 
perfused myocardium was stained with Evans blue dye, 
whereas the occluded vascular bed was not. The atrium, right 
ventricle, and major vessels were removed from the heart, 
and the AAR was separated from the non-ischemic area. 
The AAR was cut into small pieces and incubated in 0.5% 
2,3,5-triphenyltetrazolium chloride (TTC) at 37
oC for 15 
min. The non-infarcted myocardium was stained a deep red 
color with TTC, and the infarcted area (IA) remained a pale 
yellow. The sections were fixed for 24 h in 2% formalin, and 
the LV, AAR, and IA weights were determined. The AAR and 
IA were expressed as a percentage of the LV and AAR weights, 
respectively.
Measuring cTn-I 
    Twenty-four rats were assigned to the four groups to measure 
cTn-I levels. The thoracic cavity was opened to expose the heart 
and collect a 2 ml blood sample from the right ventricle. The 
serum was collected and stored at -75
oC until analysis. The 
serum cTn-I level was determined using an enzyme linked 
immunosorbent assay kit from Life Diagnostics (cat. no. 2010-
2-HS, West Chester, PA, USA). The cTn-I activity was detected 
by spectrophotometry (Infinite
Ⓡ F200, Tecan Group Ltd., 
Mönnedorf, Switzerland) at 460 nm after reacting the serum 
sample on a cTn-I antibody-coated plate.
Statistical analysis 
    All values are expressed as the mean ± SD. All statistical 
analyses were performed using SPSS software (ver. 12.0 for 
Windows, SPSS Inc., Chicago, IL, USA). The differences between 
groups were evaluated using a Friedman one-way analysis 
of variance and a post hoc Tukey’s multiple comparison test. 
Statistical significance was defined as P < 0.05. 
Results 
Hemodynamic function following I/R injury
    The hemodynamic measurements recorded after 48 h of 
reperfusion revealed LV dysfunction, as demonstrated by 
the increased LVEDP (P = 0.01) and decreased LVSP (P = 
0.01), +dP/dtmax (P = 0.0001), and -dP/dtmax (P = 0.0001) in 
the control group compared to the sham group. Propofol 
significantly inhibited the decrease in +dP/dtmax compared 
to the control group (P = 0.002) and intralipid group (P = 0.01) 
(Table 1).
Myocardial infarct size
    No significant differences between the three groups were 
observed in the AAR/LV induced by occluding the LCA territory. 
The IA weights in the control, propofol, and intralipid groups 
were 0.12 g, 0.08 g (P = 0.031 vs. control group), and 0.09 g, 
respectively. The IA/AAR in the control, propofol, and intralipid 
groups was 49.8%, 32.6% (P = 0.014 vs. control group), and 
33.4% (P = 0.045 vs. control group), respectively. No significant 
differences in IA weight and IA/AAR were found between the 
propofol and intralipid groups (Table 2). 
Table 1. Hemodynamic Data after 48 h of Reperfusion
LVSP
(mmHg)
LVEDP
(mmHg)
HR
(beats/min)
+dP/dtmax
(mmHg/s)
-dP/dtmax
(mmHg/s)
SBP
(mmHg)
DBP
(mmHg)
Sham group (n = 10)
Control group (n = 10)
Propofol group (n = 10)
Intralipid group (n = 10)
109 ± 6.7*
  93 ± 6.8*
  97 ± 5.3*
  93 ± 5.1*
12.2 ± 1.1
14.8 ± 2.1*
13.5 ± 2.0
14.6 ± 2.3*
296 ± 33
290 ± 24
290 ± 26
284 ± 27
3,754 ± 312
2,803 ± 220*
3,240 ± 235*,†,‡
2,901 ± 231*
-3,285 ± 357
-2,319 ± 267*
-2,599 ± 310*
-2,356 ± 227*
106 ± 8.9
  90 ± 6.9*
  96 ± 4.3*
  91 ± 5.2*
75 ± 7.1
63 ± 4.7*
70 ± 5.3
65 ± 4.4*
The values are mean ± SD. n: number of rats, LVSP: left ventricular systolic pressure, LVEDP: left ventricular end diastolic pressure, HR: heart 
rate, +dP/dtmax: peak rate of intraventricular pressure increase, -dP/dtmax: peak rate of intraventricular pressure decrease, SBP: systolic blood 
pressure, DBP: diastolic blood pressure. *P < 0.05 compared to the sham group. 
†P < 0.05 compared to the control group. 
‡P < 0.05 compared 
to the propofol group.381 www.ekja.org
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Serum cTn-I levels 
    The serum cTn-I levels in the sham, control, propofol, and 
intralipid groups were 0.087 ng/ml, 12.2 ng/ml (P = 0.0001 vs. 
sham group), 6.7 ng/ml (P = 0.0001 vs. sham group, P = 0.0001 
vs. control group), and 10.4 ng/ml (P = 0.0001 vs. sham group, 
P = 0.005 vs. intralipid group), respectively (Fig. 1). The I/
R-induced serum cTn-I level was reduced by propofol infusion 
during the peri-ischemic period.
Discussion
    Propofol improved myocardial contractility, reduced my-
ocardial infarct size, and decreased serum cTn-I levels after a 
regional I/R injury in an in vivo rat heart model after 48 h of 
reperfusion. It has been reported that necrotic cell death reaches 
a peak at 24 h, whereas apoptotic cell death in the peri-necrotic 
myocardium develops progressively to 72 h during the late 
reperfusion period [10]. Although many reports have addressed 
the myocardial protective effect of propofol, few reports 
have examined the long-term effects. Myocardial infarction 
was extended progressively; therefore, the hemodynamic 
parameters, infarct size, and cTn-I were measured after 48 h of 
reperfusion to identify the delayed myocardial protective effect 
of propofol. Propofol improved cardiac function and reduced 
myocardial infarct size following a regional I/R injury in an in 
vivo rat heart model after a 48-h reperfusion.
    Of the hemodynamic parameters, +dP/dtmax represents 
myocardial contractility, and +dP/dtmax improved significantly 
in the propofol group compared to the control group, indicating 
that the myocardial protective effect of propofol was maintained 
after a 48 h reperfusion. The effect of myocardial protection 
was not related to intralipids. Diastolic function is another 
important myocardial contractility factor, which is represented 
by -dP/dtmax. However, in this study, -dP/dtmax did not 
improve significantly in the propofol group compared to the 
control group. 
    Although quantitating myocardial infarct size is subjective, 
it is a useful means to evaluate myocardial infarct size. A 
prolonged reperfusion time of 24-72 h allows for a more 
precise histological quantitation of necrosis than do shorter 
times and excludes the possibility that an apparent reduction 
in infarct size observed early after the onset of reperfusion is 
subsequently overcome by delayed necrosis or apoptosis [14]. 
The infarct size was significantly smaller in the propofol and 
intralipid groups than in the control group, indicating that 
intralipid has a partial myocardial protective effect. 
    The role of cTn-I and cTn-T measurements in the diagnosis of 
patients with acute coronary syndrome is well established [15]. 
These measurements provide a definitive biochemical test to 
confirm or exclude myocardial necrosis. Troponin assays are 
not only more sensitive but are also more specific than a CK-MB 
assay. In this study, the I/R injury increased cTn-I serum levels, 
which were reduced by propofol infusion during the peri-
ischemic period.
    This study had some limitations. First, the frequent lack 
of comparisons with a non-anesthetized control group is a 
difficulty when examining the effects of these intravenous 
anesthetic agents, particularly in vivo, because many 
studies have used acutely instrumented models requiring 
basal anesthesia [16-18]. Second, ketamine blocks the 
cardioprotective effects of ischemic preconditioning [19]. 
However, the effect is stereoselective, and R(-)-ketamine 
mainly blocks the effects of preconditioning, whereas racemic 
ketamine does not [20,21]. Racemic ketamine was used as 
Table 2. Body, Left Ventricle, Infarct Area Weight, and Infarct Area Weight as a Percentage of the Area at Risk
Sham group
(n = 10)
Control group
(n = 10)
Propofol group 
(n = 10)
Intralipid group
(n = 10)
Body weight (g)
LV weight (g)
Infarct area weight (g)
Infarct area weight /area at risk (%)
  228 ± 8.4
0.56 ± 0.05
 230 ± 7.4
0.58 ± 0.06
0.12 ± 0.05
49.8 ± 19.5
 227 ± 8.5
0.58 ± 0.07
0.08 ± 0.04*
32.6 ± 16.6*
 227 ± 6.4
0.59 ± 0.06
0.09 ± 0.04
33.4 ± 17.0*
The values are mean ± SD. n: number of rats, LV: left ventricle. *P < 0.05 compared to the control group.
Fig. 1. Serum cTn-I levels in the different groups undergoing cardiac 
ischemia/reperfusion injury. The values are the mean ± SD. cTn-I: 
cardiac troponin I. *P < 0.05 compared to the sham group. 
†P < 0.05 
compared to the control group. 
‡P < 0.05 compared to the propofol group.382 www.ekja.org
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the anesthetic drug in this study because it has the lowest 
myocardial protective effect compared to other anesthetic 
drugs. Third, the hemodynamic parameters were only checked 
at 48 h after reperfusion. They could not be checked at baseline 
or during the ischemic period due to technical difficulties.
    In conclusion, a clinically relevant propofol concentration was 
associated with a delayed myocardial protective effect after a 
regional I/R injury in an in vivo rat heart model. This myocardial 
protective effect might not be due to delayed myocardial injury, 
but to the myocardial protective effect of propofol itself.
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